Vunakizumab (Anti-CTLA-8 / IL-17a)

Synonyms: null

Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.

Vunakizumab (Anti-CTLA-8 / IL-17a)

Purity & Quality Control

Choose Selective Interleukins Inhibitors

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.

Product Details

CAS No. 1792181-33-9
Molecular Weight 146.28
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac,pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vunakizumab (Anti-CTLA-8 / IL-17a) | Vunakizumab (Anti-CTLA-8 / IL-17a) supplier | purchase Vunakizumab (Anti-CTLA-8 / IL-17a) | Vunakizumab (Anti-CTLA-8 / IL-17a) cost | Vunakizumab (Anti-CTLA-8 / IL-17a) manufacturer | order Vunakizumab (Anti-CTLA-8 / IL-17a) | Vunakizumab (Anti-CTLA-8 / IL-17a) distributor